52 related articles for article (PubMed ID: 27155203)
1. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
Dhaliwal K; Griffin M; Denton CP; Butler PEM
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756
[TBL] [Abstract][Full Text] [Related]
2. A case report of the beneficial effects of botulinum toxin type A on Raynaud phenomenon in a patient with lung cancer.
Wang L; Lei QS; Liu YY; Song GJ; Song CL
Medicine (Baltimore); 2016 Oct; 95(40):e5092. PubMed ID: 27749585
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of botulinum toxin in treating scleroderma-associated raynaud's phenomenon: a systematic review and meta-analysis.
Elrosasy A; Abo Zeid M; Cadri S; Fahmy BM; Elzeftawy MA; Mohammed F; Ramadan A
Arch Dermatol Res; 2024 Apr; 316(5):122. PubMed ID: 38630277
[No Abstract] [Full Text] [Related]
4. Extraction and injection of botulinum toxin with less wastage.
Lee KWA; Chan LKW; Hung LC; Wu R; Wong S; Wan J; Yi KH
Skin Res Technol; 2024 Jul; 30(7):e13816. PubMed ID: 38925591
[No Abstract] [Full Text] [Related]
5. Naevoid miliaria profunda, successfully treated with botulinum toxin.
Berry W; D'Arcy C; Welsh B; Orchard D; Bekhor PS; Robertson SJ
Australas J Dermatol; 2024 Jun; 65(4):399-401. PubMed ID: 38530143
[No Abstract] [Full Text] [Related]
6. Botulinum toxin A in the treatment of Raynaud's phenomenon: a systematic review.
Żebryk P; Puszczewicz MJ
Arch Med Sci; 2016 Aug; 12(4):864-70. PubMed ID: 27478469
[TBL] [Abstract][Full Text] [Related]
7. The role of botulinum toxin in vasospastic disorders of the hand.
Neumeister MW
Hand Clin; 2015 Feb; 31(1):23-37. PubMed ID: 25455354
[TBL] [Abstract][Full Text] [Related]
8. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.
Fregene A; Ditmars D; Siddiqui A
J Hand Surg Am; 2009 Mar; 34(3):446-52. PubMed ID: 19258141
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin-A for the treatment of Raynaud syndrome.
Smith L; Polsky D; Franks AG
Arch Dermatol; 2012 Apr; 148(4):426-8. PubMed ID: 22508867
[No Abstract] [Full Text] [Related]
11. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
Neumeister MW
J Hand Surg Am; 2010 Dec; 35(12):2085-92. PubMed ID: 21134617
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin A treatment of Raynaud's phenomenon: a review.
Iorio ML; Masden DL; Higgins JP
Semin Arthritis Rheum; 2012 Feb; 41(4):599-603. PubMed ID: 21868066
[TBL] [Abstract][Full Text] [Related]
13. Management of Raynaud's digital ulcer with interdigital Botulinum toxin A injection.
Navarro EP; Cañas CA; Tobón GJ
Rheumatology (Oxford); 2016 Jul; 55(7):1216. PubMed ID: 27155203
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
